咪唑斯汀联合赛庚啶递减疗法治疗慢性荨麻疹94例临床观察

Clinical Observation of 94 Cases of the Decreasing Therapy of Mizolastine Combined with Cyproheptadine in Treating Chronic Urticarial

目的探讨咪唑斯汀联合赛庚啶递减疗法治疗慢性荨麻疹的临床效果和安全性。方法选取本院2014年1月-2016年1月收治的188例慢性荨麻疹患者,随机等分为两组。全部患者予口服咪唑斯汀10mg,1次/d,六个疗程共10周,同时治疗组还予赛庚啶递减疗法治疗。比较两组患者治疗3周和10周时的临床疗效和治疗前后IL-2及IL-4水平,随访3个月评价复发情况。结果治疗3周时两组患者有效率差异无统计学意义(P>0.05),治疗10周时两组患者有效率差异及IL-2和IL-4水平差异均有统计学意义(P均<0.05),即治疗组疗效优于对照组疗效。另外,治疗组复发率明显低于对照组的复发率(P<0.05)。结论咪唑斯汀联合赛庚啶递减疗法治疗慢性荨麻疹的效果切实,安全性高,且复发率较低,临床参考价值较高。

Objective To investigate the clinical effect and safety of the decreasing therapy of mizolastine combined with cyproheptadine in treating chronic urticaria. Methods One hundred and eighty-eight cases of patients with chronic urticaria in our hospital from January 2014 to January 2016 were selected and randomly divided into two groups. All patients were given mizolastine orally 10mg, 1times/d, six courses of treatment lasted for 10 weeks, while patients in the observation group at the same time were treated with the decreasing therapy of cyproheptadine. The clinical efficacy of 3 and 10 weeks and levels of IL-2 and IL-4 before and after treatment in two groups were compared, then following up for 3 months and evaluating relapse. Results Treatment for 3 weeks, total effective rate in two groups had no statistical significance （ P 〉 0. 05 ）, difference of total effective rate and IL-2 and IL-4 level in two groups had statistical significance after treatment for 10 weeks（ P 〈 0. 05）, namely the curative effect of treatment group was better than that of control group. In addition, recurrence rate of treatment group was obviously lower than the control group（P 〈 0. 05 ）. Conclusion The decreasing therapy of mizolastine combined with cyproheptadine in treating chronic urticaria had good clinical effect, safety, low recurrence rate was and higher clinical reference value.